Back to results
US 2004/0171802 A1Published application
Haemophilus influenzae antigens and corresponding dna fragments
OwnerJosee Hamel, France Couture +6inventors
InventorsJosee Hamel, France Couture, Bernard R. Brodeur, Denis Martin, Catherine Quellet, Mireille Tremblay, Annie Charbonneau, Catherine Vayssier
Life of this patent
Estimating the term…
Abstract
The present invention relates to polypeptides of Haemophilus influenzae which may be used for prophylaxis, diagnostic and/or therapy purposes.
Claims30
An isolated polynucleotide comprising a polynucleotide chosen from;
- (a) a polynucleotide encoding a polypeptide having at least 70% identity to a second polypeptide comprising a sequence chosen from:
- SEQ ID NOs:
- 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 and 24 or fragments or analogs thereof;
- (b) a polynucleotide encoding a polypeptide having at least 95% identity to a second polypeptide comprising a sequence chosen from:
- SEQ ID NOs:
- 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 and 24 or fragments or analogs thereof;
- (c) a polynucleotide encoding a polypeptide comprising a sequence chosen from:
- SEQ ID NOs:
- 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 and 24 or fragments or analogs thereof;
- (d) a polynucleotide encoding a polypeptide capable of generating antibodies having binding specificity for a polypeptide having a sequence chosen from SEQ ID NOs:
- 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 and 24 or fragments or analogs thereof;
- (e) a polynucleotide encoding an epitope bearing portion of a polypeptide having a sequence chosen from SEQ ID NOs:
- 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 and 24 or fragments or analogs thereof;
- (f) a polynucleotide complementary to a polynucleotide in (a), (b), (c), (d) or (e).
11 more elements
An isolated polynucleotide comprising a polynucleotide chosen from;
- (a) a polynucleotide encoding a polypeptide having at least 70% identity to a second polypeptide comprising a sequence chosen from:
- SEQ ID NOs:
- 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 and 24;
- (b) a polynucleotide encoding a polypeptide having at least 95% identity to a second polypeptide comprising a sequence chosen from:
- SEQ ID NOs:
- 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 and 24;
- (c) a polynucleotide encoding a polypeptide comprising a sequence chosen from:
- SEQ ID NOs:
- 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 and 24;
- (d) a polynucleotide encoding a polypeptide capable of generating antibodies having binding specificity for a polypeptide having a sequence chosen from SEQ ID NOs:
- 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 and 24;
- (e) a polynucleotide encoding an epitope bearing portion of a polypeptide having a sequence chosen from SEQ ID NOs:
- 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 and 24;
- (f) a polynucleotide complementary to a polynucleotide in (a), (b), (c), (d) or (e).
11 more elements
An isolated polypeptide comprising a member chosen from:
- (a) a polypeptide having at least 70% identity to a second polypeptide having an amino acid sequence chosen from:
- SEQ ID NOs:
- 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 and 24 or fragments or analogs thereof;
- (b) a polypeptide having at least 95% identity to a second polypeptide having an amino acid sequence chosen from:
- SEQ ID NOs:
- 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 and 24 or fragments or analogs thereof;
- (c) a polypeptide comprising a sequence chosen from:
- SEQ ID NOs:
- 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 and 24 or fragments or analogs thereof;
- (d) a polypeptide capable of generating antibodies having binding specificity for a polypeptide having a sequence chosen from SEQ ID NOs:
- 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 and 24 or fragments or analogs thereof;
- (e) an epitope bearing portion of a polypeptide having a sequence chosen from SEQ ID NOs:
- 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 and 24 or fragments or analogs thereof;
- (f) the polypeptide of (a), (b), (c), (d) or (e) wherein the N-terminal Met residue is deleted;
- (g) the polypeptide of (a), (b), (c), (d) or (e) wherein the secretory amino acid sequence is deleted.
12 more elements
An isolated polypeptide comprising a member chosen from:
- (a) a polypeptide having at least 70% identity to a second polypeptide having an amino acid sequence chosen from:
- SEQ ID NOs:
- 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 and 24;
- (b) a polypeptide having at least 95% identity to a second polypeptide having an amino acid sequence chosen from:
- SEQ ID NOs:
- 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 and 24;
- (c) a polypeptide comprising a sequence chosen from:
- SEQ ID NOs:
- 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 and 24;
- (d) a polypeptide capable of generating antibodies having binding specificity for a polypeptide having a sequence chosen from SEQ ID NOs:
- 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 and 24;
- (e) an epitope bearing portion of a polypeptide having a sequence chosen from SEQ ID NOs:
- 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 and 24;
- (f) the polypeptide of (a), (b), (c), (d) or (e) wherein the N-terminal Met residue is deleted;
- (g) the polypeptide of (a), (b), (c), (d) or (e) wherein the secretory amino acid sequence is deleted.
12 more elements
A chimeric polypeptide comprising two or more polypeptides having a sequence chosen from SEQ ID NOs:
- 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 and 24 or fragments or analogs thereof;
- provided that the polypeptides are linked as to formed a chimeric polypeptide.
A chimeric polypeptide comprising two or more polypeptides having a sequence chosen from SEQ ID NOs:
- 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 and 24 or fragments or analogs thereof;
- provided that the polypeptides are linked as to formed a chimeric polypeptide.
Dependencies are inferred from the claim text.